Veterinary Drug Approval Process

Veterinary Drug Approval Course Description

The development and commercialization of veterinary pharmaceutical products in the United States requires a thorough understanding of the regulatory framework established by the U.S. Food and Drug Administration (FDA), particularly its Center for Veterinary Medicine (CVM).

This comprehensive two-day interactive training seminar provides a practical understanding of the FDA regulatory pathways, scientific requirements, technical submissions and compliance obligations involved in developing and obtaining approval for new animal drug products.

Participants will gain an understanding of the complete veterinary drug development and approval lifecycle, beginning with early product development and Investigational New Animal Drug (INAD) submissions, through the preparation and review of New Animal Drug Applications (NADA), Conditional New Animal Drug Applications (CNADA), and Abbreviated New Animal Drug Applications (ANADA).

The programme examines the key technical sections of a veterinary drug application, including Chemistry, Manufacturing and Controls (CMC), Effectiveness, Target Animal Safety (TAS), Human Food Safety, Environmental Impact, Labeling and supporting documentation. It also explores the regulatory considerations associated with clinical field studies, manufacturing controls, bioequivalence, product labeling and post-approval compliance.

Special Focus: 2026 FDA Veterinary Regulatory Developments

The seminar incorporates important FDA/CVM developments and regulatory guidance updates relevant to veterinary drug sponsors and animal health companies in 2026, including:

• Residue Analytical Method Requirements: FDA's October 2026 Risk-Based Tiered Approach pilot and One Method Approach for demonstrating residue analytical method practicability in new animal drug development.
• Antimicrobial Resistance: Final FDA Guidance for Industry (GFI) #152 issued in August 2026, addressing the evaluation of antimicrobial new animal drugs and their microbiological effects on bacteria of human health concern.
• Minor Use and Minor Species (MUMS): FDA's 2026–2028 MUMS Blueprint for Success and its proposed strategic priorities for expanding veterinary drug development for underserved animal populations.
• Animal Drug Compounding: Proposed FDA draft GFI #256B (August 2026) addressing compounding animal drugs from bulk drug substances under CGMP in federally registered facilities.
• Veterinary Monoclonal Antibodies: September 2026 draft GFI #298 (VICH GL62) on target animal safety evaluation of veterinary monoclonal antibody products.
• Animal Drug User Fee Programs: Overview of ADUFA and AGDUFA, including the FY 2027 user fee rates and their implications for animal drug sponsors.

Course Highlights :

• Complete overview of the US FDA veterinary drug approval framework.
• INAD, NADA, CNADA and ANADA submission pathways.
• Practical preparation of NADA technical sections.
• CMC, target animal safety and effectiveness requirements.
• Clinical field study design, conduct and documentation.
• Human food safety and residue evaluation requirements.
• 2026 FDA/CVM regulatory and guidance developments.
• New risk-based approaches to residue analytical method requirements.
• Antimicrobial resistance assessment and GFI #152.
• MUMS development opportunities and regulatory incentives.
• Veterinary drug compounding and CGMP considerations.
• Post-approval regulatory obligations, pharmacovigilance and compliance.

Training Agenda

DAY 1 – FDA Veterinary Drug Development, Regulatory Pathways & Technical Submission Requirements

Module 1: Introduction to the US Veterinary Drug Regulatory Framework

• Overview of the FDA and Center for Veterinary Medicine (CVM).
• FDA jurisdiction and responsibilities for animal health products.
• Key legislation and regulatory framework:
• Federal Food, Drug, and Cosmetic Act (FD&C Act).
• Animal Drug Availability Act (ADAA).
• Animal Medicinal Drug Use Clarification Act (AMDUCA).
• Minor Use and Minor Species Animal Health Act.
• Regulatory distinctions between FDA, USDA and EPA.
• Differences between human and veterinary drug approval pathways.
• Overview of 21 CFR requirements and applicable FDA guidance documents.
• Regulatory resources, databases and electronic submission resources.

Module 2: Veterinary Drug Development and FDA Engagement

• Product discovery, development strategy and preliminary regulatory considerations.
• Intellectual property, patent protection and market exclusivity.
• Opening and maintaining an Investigational New Animal Drug (INAD) file.
• INAD submission requirements and supporting documentation.
• FDA/CVM phased review process.
• Early submission of technical information and development data.
• Planning and conducting meetings with CVM.
• Regulatory interactions, sponsor responsibilities and submission strategies.
• GLP, GCP and GMP considerations during veterinary drug development.

Module 3: Developing New Animal Drug Application (NADA) Technical Sections

Chemistry, Manufacturing and Controls (CMC)

• Drug substance and drug product characterization.
• Manufacturing processes and process controls.
• Specifications, analytical methods and stability.
• Quality control and manufacturing documentation.
• CMC submission strategies and common deficiencies.
• Relevant FDA CMC guidance and VICH harmonization considerations.

Effectiveness and Clinical Field Studies

• Demonstrating substantial evidence of effectiveness.
• Planning and conducting veterinary clinical field studies.
• Study protocols, endpoints and statistical considerations.
• Selection of study sites, investigators and target animal populations.
• Data collection, monitoring and final study reports.
• FDA expectations for study documentation and data integrity.

Module 4: Innovative Clinical Development Approaches

• Use of foreign investigational study data – GFI #265.
• Real-world data and real-world evidence – GFI #266.
• Biomarkers and surrogate endpoints – GFI #267.
• Adaptive and other innovative effectiveness study designs – GFI #268.
• Regulatory considerations for innovative veterinary drug development.
• Practical challenges in generating acceptable effectiveness evidence.

DAY 2 – Safety, Regulatory Approval, 2026 FDA Updates & Post-Approval Compliance

Module 5: Target Animal Safety and Human Food Safety

Target Animal Safety (TAS)

• FDA requirements for target animal safety evaluation.
• Safety studies and assessment of adverse reactions.
• Dose selection and safety margins.
• Safety evaluation across different animal species.
• Study design, statistical analysis and reporting.
• Veterinary monoclonal antibody products: September 2026 draft GFI #298 (VICH GL62).

Human Food Safety

• Evaluation of residues in food-producing animals.
• Toxicology, metabolism and residue depletion studies.
• Establishing acceptable daily intake and safe concentrations.
• Withdrawal periods and residue tolerances.
• Environmental and consumer safety considerations.

Module 6: 2026 FDA Regulatory Developments and Emerging Requirements

• October 2026 FDA Risk-Based Tiered Approach pilot for residue analytical method practicability.
• One Method Approach: integrating analytical method validation with residue depletion studies.
• Implications for study planning, regulatory submissions and development timelines.
• Final FDA GFI #152 (August 2026): Antimicrobial resistance risk assessment.
• Evaluation of antimicrobial drugs based on their importance to human medicine.
• FDA MUMS Blueprint for Success 2026–2028.
• New opportunities and proposed priorities for minor use and minor species drug development.
• Draft GFI #256B (August 2026): Animal drug compounding from bulk drug substances in federally registered facilities under CGMP.
• ADUFA and AGDUFA user fee programmes, including FY 2027 rates.
• Monitoring FDA guidance developments, draft guidance and implementation status.

Module 7: Additional Regulatory Pathways and Specialized Applications

Conditional New Animal Drug Approval (CNADA)

• Eligibility and regulatory requirements.
• Substantial evidence of effectiveness and reasonable expectation of effectiveness.
• Conditional approval process and annual renewal considerations.
• Transition from conditional to full approval.

Generic Animal Drugs (ANADA)

• Overview of the Abbreviated New Animal Drug Application.
• JINAD process and submission requirements.
• Bioequivalence and pharmaceutical equivalence.
• CMC, safety and effectiveness considerations.
• Generic product labeling and approval requirements.

Minor Use and Minor Species (MUMS)

• Designation and eligibility requirements.
• Indexing pathway for qualifying minor species drugs.
• Marketing exclusivity and incentives.
• MUMS grants and development opportunities.

Module 8: Labeling, Regulatory Approval and Commercialization

• FDA veterinary drug labeling requirements.
• Prescription and over-the-counter veterinary drug products.
• Freedom of Information (FOI) summaries.
• All Other Information (AOI).
• Marketing exclusivity and intellectual property considerations.
• Animal Drug User Fee Act requirements.
• Regulatory considerations before commercial distribution.

Module 9: Post-Approval Compliance and Regulatory Obligations

• Post-approval CMC changes and supplements.
• Manufacturing compliance and CGMP expectations.
• Pharmacovigilance and adverse drug experience reporting.
• Product quality complaints and safety signals.
• FDA inspections, observations and enforcement considerations.
• Extra-label drug use under AMDUCA.
• Veterinary drug compounding and applicable enforcement policies.
• Regulatory considerations for animal feed, medicated feed, supplements and veterinary medical devices.
• Ongoing regulatory maintenance and lifecycle management.

Module 10: Practical Case Studies and Interactive Discussion

• Reviewing a hypothetical veterinary drug development pathway from INAD to NADA.
• Identifying key technical and regulatory requirements for an NADA submission.
• Evaluating a clinical study and CMC submission scenario.
• Assessing regulatory challenges associated with food-producing animal drugs.
• Discussing common submission deficiencies and potential FDA concerns.
• Questions, answers and faculty discussion.
  

Who will Benefit

This course is designed primarily for people tasked with developing new animal drugs for an animal health company or a human pharmaceutical company. This includes individuals responsible for overseeing regulatory affairs, developing veterinary drug products, or evaluating new technologies or applications. Among others, this includes:

• Personnel new to the Animal Health Industry
• CRO professionals
• Entrepreneurs looking to add value to their products
• Regulatory professionals
• Compliance professionals
• U.S. Agents of Foreign Corporations
• Legal Professionals
• Financial Advisors and Institutional Investors